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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idFigure 1. Summary of RNA copy, cytokine levels (represented by interleukin 6
(IL-6), lymphocyte levels (represented by CD4 cells), and hemorrhage severity
(D-dimer as an indicator) in EBOV infection cases with fatal and non-fatal outcomes.
Data for these four parameters were retrieved from the references.6–8 Arrows show
the times of antiviral agent application and the clinic visit.When should antiviral drugs be used for the
patient with an Ebola virus infection?
Infection with the Ebola virus (EBOV) causes a severe
hemorrhagic fever syndrome with a case-fatality rate of up to
90%. Kant recently proposed a research program entitled
‘‘Pharmacophore modeling, database mining and biological
evaluation to identify novel structurally diverse compounds as
potential anti-Ebola drugs’’.1 However, the optimal timing of
medication with these antiviral drugs remains unclear.
Wong et al. recently reported the cases of six physicians and
nurses with occupational exposure to Ebola virus in West Africa who
received the antiviral agent rVSV-ZEBOV (rVSV-vectored vaccine
expressing Ebola surface glycoprotein) or TKM-100802 (a lipid-
bound small interfering RNA) for post-exposure prophylaxis.2 All
of these patients had self-limited symptoms after treatment, but
none developed Ebola virus disease, indicating the effectiveness of
these antiviral drugs.2
However, there are also some controversial reports. Oral
favipiravir therapy showed a small beneﬁt in patients with
medium to high viremia (RT-PCR cycle threshold value <20),
but was not effective in those with very high viremia .3 An interim
analysis of a trial of rVSV-ZEBOV in Guinea indicated that in the
immediate vaccination group, there were no cases of Ebola virus
disease with symptom onset at least 10 days after randomization,
whereas in the delayed vaccination group (21 days later) there
were 16 cases of Ebola virus disease from seven clusters.4
Moreover, there are only two case reports for the drug TKM-
100802. It is still unclear what role the TKM-100802 had in the
recovery of these patients.5
Why were these anti-EBOV agents sometimes  ineffective? A
previous study showed that viral RNA copy levels in patients who
died averaged 2 log10 higher than those in patients who survived.
6
Furthermore, this extraordinarily high viral load is associated
with an aberrant innate immunity characterized by a ‘cytokine
storm’ (e.g., high levels of interleukin 6), which leads to a massive
loss (cell death) of CD4 and CD8 lymphocytes6,7 and a fast-
developing hemorrhage (e.g., higher levels of D-dimer) during the
later stage of infection, such as at the time of the ﬁrst clinic visit
(Figure 1).8
In contrast, before the onset of symptoms, the viral load is much
lower in both survivors and non-survivors. For example, patients at
the time of the ﬁrst clinic visit have 2 log10 higher levels of viral
RNA than those at the onset of symptoms, and 4 log10 higher levels
than those at 7 days before the onset of symptoms (Figure 1).
For the later-stage patients, host-directed therapeutic strate-
gies may be more effective than the anti-EBOV agents. For
example, local physicians in Sierra Leone treated approximately
100 consecutive Ebola patients with atorvastatin and irbesartan,
and all but two inadequately treated patients survived, although
these data need to be reviewed and validated.9 A hypotheticalhttp://dx.doi.org/10.1016/j.ijid.2016.07.013
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).treatment protocol to treat EBOV infection with the combined use
of miglustat and toremifene has also been proposed recently.10ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
LETTER TO THE EDITOR / International Journal of Infectious Diseases 50 (2016) 21–2222In summary, antiviral drugs should be used as early as possible
(ideally before the onset of symptoms). Combinations of antiviral
treatments and host-directed therapeutic strategies may be
helpful for the late-stage patients.
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